Navitas Semiconductor Corporation (NVTS) shares ended the last trading session 24.7% higher at $8.47. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.1% loss over the past four weeks.Navitas Semiconductor is benefiting from its innovative GaN and silicon carbide technologies, enabling advancements in AI data centers, EVs, solar microinverters, and energy storage systems. This company is expected to post quarterly ...

RT Addressable 🎯 (@addressableid)In the last year, stablecoin transaction volume in Iran grew over 600%.In Nigeria, over 250%.In Turkey, over 100%.While you're worried about a 2% inflation target, they're worried about their currency collapsing.You see crypto as an investment.They see it as an escape hatch.This isn’t theory. It's a conclusion drawn from analyzing 23 million wallets with @MessariCrypto for their new "State of Stablecoins" report where we found the average growth across high-inflation countri ...

Northrop Grumman (NOC) Q2 2025 Earnings Call July 22, 2025 09:30 AM ET Company ParticipantsTodd Ernst - VP - IRKathy Warden - Chair, CEO & PresidentKenneth Crews - Corporate VP & CFODouglas Harned - Managing DirectorGavin Parsons - Director - Aerospace & Defense Equity ResearchRonald Epstein - MD - Aerospace & DefenseScott Deuschle - Director - Aerospace & Defense Equity ResearchKristine Liwag - Executive DirectorRobert Stallard - PartnerSheila Kahyaoglu - Aerospace & Defense & Airlines Equity ResearchSeth ...

Northrop Grumman (NOC) Q2 2025 Earnings Call July 22, 2025 09:30 AM ET Speaker0Good day, ladies and gentlemen, and welcome to Northrop Grumman's Second Quarter twenty twenty five Conference Call. Today's call is being recorded. My name is Josh, and I will be your operator today. At this time, all participants are in a listen only mode. I would like to turn the call over to your host, Mr.Todd Ernst, Vice President, Investor Relations. Mr. Ernst, please proceed.Speaker1Thanks, Josh, and good morning, everyone ...

Financial Performance & Growth - NXP targets high single-digit organic revenue growth and gross margin expansion above 60%[10, 123] - NXP aims to double non-GAAP EPS by 2030+[11, 124] - NXP's revenue grew at a 7% compound annual growth rate (CAGR) over the past five years, reaching $12.6 billion in 2024[60] - Non-GAAP operating profit increased at an 11% CAGR over five years, reaching $4.4 billion in 2024[61] - NXP's non-GAAP free cash flow was $2.1 billion in 2024[66] Market & Strategy - NXP is focused on RMS (Relative Market Share) leadership and system leadership to drive profitable growth[24, 25] - Automotive and Industrial & IoT are key growth drivers at the intelligent edge, within a $1.3 trillion semiconductor market opportunity[16, 17] - NXP projects revenue in Automotive to grow from $7.2 billion in 2024 to approximately $9.5 billion by 2027[42] - NXP anticipates revenue in Industrial & IoT to increase from $2.3 billion in 2024 to around $3.1 billion by 2027[49] Capital Allocation & Debt - NXP is committed to returning 100% of excess free cash flow to owners[10, 123] - NXP's cumulative capital return from 2018 to 2024 was $19.2 billion, representing 109% of non-GAAP free cash flow[90] - NXP's net debt stood at $8.308 billion with a net leverage of 1.8x as of Q2 2025[93]

How To Call Out Workplace Problems Without Getting Labeled ‘Difficult’ https://t.co/GP35gIauW2 https://t.co/GP35gIauW2 ...

How To Call Out Workplace Problems Without Getting Labeled ‘Difficult’ https://t.co/0mWeBejD3i https://t.co/0mWeBejD3i ...

remember when crypto projects just did one thing?ethena going from stablecoin to nasdaq-listed treasury firmkaito evolving past launchpad into AI + incubationthe next wave isn't about products. it's about building entire financial systems.infrastructure game got serious ...

ab 18 July 2025 Global Research China Healthcare China preclinical CRO expert call takeaways H125: slight price & volume recovery; tipping point may not occur until 2026 On 18 July, we invited a senior executive from a domestic medium-sized preclinical CRO firm to share his views. He noted a slight recovery in China's preclinical CRO industry. Overall order inflow has increased modestly YoY for both volume (up <10%) and price (up 5-10%) YTD, with profits staying low. In his view, pharmaceutical R&D is gener ...

Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Qatar Infection Control Market Report and Forecast 2025-2034" has been added to ResearchAndMarkets.com's offering.The Qatar infection control market is projected to experience substantial growth, with its value expected to increase from USD 104.22 million in 2024 to USD 145.60 million by 2034, representing a CAGR of 3.40% during the forecast period. This anticipated growth is fueled by heightened interest in automated and AI-powered sterilization systems, offe ...